Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

Open to people ages 18-65

• A pre-existing diagnosis of ADPKD as defined in the protocol
• Willing and able to comply with scheduled visits and other study procedures
• Participants with ADPKD with Mayo imaging classification (MIC) status of 1B (with htTKV ≥250 mL/m), 1C, 1D, or 1E confirmed by abdominal MRI obtained during screening
• Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 25 milliliter per minute (mL/min)/1.73 square meter (m²)

• History of kidney disease other than ADPKD that in the opinion of the investigator would independently impact the natural history of ADPKD
• History of solid organ or bone marrow transplantation or nephrectomy
• Ongoing renal replacement therapy or planning to start renal replacement therapy within 12 months of screening

Other protocol defined Inclusion/Exclusion criteria will apply.